Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials
Journal of the European Academy of Dermatology and Venereology | Sep 17, 2019
Adalimumab for nail psoriasis: Efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
Journal of the European Academy of Dermatology and Venereology | Sep 12, 2019
Adalimumab for nail psoriasis: Efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
Journal of the European Academy of Dermatology and Venereology | Aug 27, 2019
Most read this week